Karen L. Reckamp, MD, MS

home / authors / karen-l-reckamp-md-ms

Articles

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

Edward S. Kim, MD, MBA;Heather Wakelee, MD;Karen L. Reckamp, MD, MS;Edgardo S. Santos, MD, FACP, FCCP;Lyudmila Bazhenova, MD
September 13th 2023

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Read More

Karen L. Reckamp, MD, MS, professor of medicine, director, Division of Medical Oncology and Lung Institute, Cedars-Sinai Medical Center, associate director, Clinical Research, Cedars-Sinai Cancer Institute

Dr Reckamp on the Landscape of Current and Emerging ADCs in NSCLC

Karen L. Reckamp, MD, MS
August 9th 2023

Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.

Read More

Karen L. Reckamp, MD, MS, professor of medicine, director, Division of Medical Oncology and Lung Institute, Cedars-Sinai Medical Center, associate director, Clinical Research, Cedars-Sinai Cancer Institute

Dr Reckamp on the Effect of Adjuvant Atezolizumab on Patient Outcomes in Resectable Stage IB-IIIA NSCLC

Karen L. Reckamp, MD, MS
April 21st 2023

Karen L. Reckamp, MD, MS, discusses updated findings from the phase 2 LCMC3 trial in resectable stage IB to IIIB non–small cell lung cancer.

Read More

Dr. Reckamp on Targeted Therapy Options for Rare Mutations in NSCLC

Dr. Reckamp on Targeted Therapy Options for Rare Mutations in NSCLC

Karen L. Reckamp, MD, MS
February 28th 2020

Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.

Read More

Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer

Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer

Emily A. Barber, BS;Karen L. Reckamp, MD, MS
June 1st 2017

This review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.

Read More